Skip to main content

Heron Therapeutics, Inc DEFA14A, filed Nov 9, 2026

Heron Therapeutics, Inc. (HRTX)

Heron Therapeutics, Inc. agreed on November 8, 2026 to sell substantially all assets to CorMedix Inc. for $145.0 million cash and 14,583,333 CorMedix shares, plus royalties and contingent earn-out payments, subject to stockholder and regulatory approvals. AI summary

DEFA14A 2026-11-09
View Original
Added on November 09, 2026